BCIQ Profiles

Company Profile Report

Omega: Flagship’s latest venture into the chromatin white space

Omega’s launch deepens Flagship’s investment in chromatin structure-based gene control

Flagship’s latest foray into white space technologies, Omega Therapeutics, is the newest company to tackle gene control by intervening at the 3-D chromatin structure level.

With a platform that homes in on the structural elements surrounding individual or small groups of genes, the company may be able to selectively regulate gene expression across a broad swath of indications.

Founded in 2017 in Flagship Pioneering’s Flagship Labs incubator, Omega Therapeutics Inc. launched from stealth on

Read the full 740 word article

How to gain access

Continue reading with a
two-week free trial.